Electric Bikes Market Will Reach a Valuation of US$62.3 Billion by The Conclusion of 2030, Predicts Persistence Market Research
January 23, 2024 01:00 ET
|
Persistence Market Research
New York, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Electric Bikes Market Gears Up for Electrifying Growth Electric Bikes, also known as e-bikes, are bicycles equipped with electric motors that assist...
LandAirSea Debuts Prototype for the Automotive Industry at NADA Show 2024
January 17, 2024 09:00 ET
|
LandAirSea Systems
PlateLocate Provides New Solution for Lost Dealer Plates, Inventory Management, Improved Dealership Experience and More
Lightweight Automotive Materials Market Races Ahead, Projected to Reach USD 112.50 Billion by 2030, Report by Persistence Market Research
January 15, 2024 07:30 ET
|
Persistence Market Research
New York, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Market Overview:The lightweight automotive materials market encompasses various product types utilized to reduce vehicle weight and improve fuel...
AMD Reveals Next-Gen Desktop Processors for Extreme PC Gaming and Creator Performance
January 08, 2024 10:30 ET
|
Advanced Micro Devices, Inc.
— AMD Ryzen™ 8000G Series desktop processors bring immense performance for gamers and creators and unlocks new personal AI experiences with Ryzen AI — — AMD bolsters desktop portfolio and...
Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers
January 04, 2024 17:25 ET
|
Gradalis, Inc.
GRAD1405 uses Gradalis’ breakthrough gene silencing bi-shRNAi technology to specifically reduce the expression of certain mutated KRAS genesExisting therapies have experienced rapid drug resistance...
Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment
December 05, 2023 08:00 ET
|
Gradalis, Inc.
Emerging research shows that targeting initial mutations expressed on a tumor cell surface, called clonal mutations, is critical in achieving a durable clinical benefitFor example, lung cancer...
Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas
November 16, 2023 15:12 ET
|
Gradalis, Inc.
DALLAS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a leader in the development of personalized anti-cancer cellular therapies for patients with solid tumors, announced today that it has been...
Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer on October 25, 2023
October 18, 2023 08:00 ET
|
Gradalis, Inc.
DALLAS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc. announced that it will host a virtual KOL discussion on the Vigil® platform entering Phase 2 for platinum-sensitive recurrent ovarian cancer...
Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication
September 28, 2023 08:00 ET
|
Gradalis, Inc.
Evidence from multiple researchers supports Vigil enhancement of clonal neoantigen effector cell response and correlation to relapse free survival and overall survival benefit Targeting clonal...
Gradalis to Participate in the Cantor Global Healthcare Conference
September 21, 2023 08:30 ET
|
Gradalis, Inc.
DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, clinical stage biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian and...